Skip to main content
. Author manuscript; available in PMC: 2022 Dec 3.
Published in final edited form as: Mol Cancer Res. 2022 Jun 3;20(6):923–937. doi: 10.1158/1541-7786.MCR-21-0781

Figure 1: Patients with liver metastatic breast tumors experience poor response to Fulv.

Figure 1:

MD Anderson Cancer Center cohort study involved 1832 patients without liver MBC and 1556 with liver MBC. Number of dead and alive patients with and without liver MBC were compared using Fisher’s exact test. Patients with ER+/HER2− liver metastatic tumors have shorter overall survival (A) and shorter survival after metastasis (B). Log-rank test was used to compare survival curves. C) Colony formation assay for MCF7-ESR1Y537S cells in Matrigel or decellularized hydrogels from different metastatic tissues and D) and efficacy of 1 μM Fulv to reduce colony number. Colonies were treated for 3 weeks. Unpaired t-test, P-values are indicated. E) Fulv dose response for colony formation of MCF7-ESR1Y537S cells in liver hydrogels. F) Quantification of colony size and number from Fig. 1E. G) Quantification of colony number for colonies in different area brackets.